Please assess the completion status of the following clinical trial:

Trial Title: Reducing Breast Cancer-related Fatigue and Improving Cognition With Non-Invasive Brain Stimulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women, 18 years of age or older~* Stage I-III breast cancer~* Treatment Status: At least 6 months and no more than 5 years after the conclusion of active breast cancer therapy, including surgery, radiation therapy and (neo)adjuvant chemotherapy, if administered. NOTE: Adjuvant HER2-targeted therapy and endocrine therapy may still be ongoing at the time of study enrollment.~* Fatigue: Moderate fatigue on most days within the past week (i.e., at least 4 out of the last 7 days), rated as ≥ 4 on a 0 (no fatigue) to 10 (worst fatigue) scale.~* Able and willing to complete study tasks as evidenced by at least the following: fluent English speaker; hearing and language comprehension; and, sufficient literacy to complete study forms and questionnaires.~* Patient understands the study regimen, its requirements, risks, and discomforts, and is able and willing to sign an informed consent form.~Exclusion Criteria:~* Evidence of recurrent breast cancer at the time of enrollment.~* Depression or anxiety as defined either by ongoing pharmacological treatment for depression or anxiety or a HADS score on initial screening.~* Dementia as assessed by a MMSE score on initial screening.~* Known pregnancy or nursing.~* Any of the following: diagnosis of schizophrenia or bipolar disorder made by a physician, seizure disorder, pacemaker, hearing aids, any metal implanted in the head, or the presence of other known current untreated causes of fatigue such as anemia or untreated hypothyroidism.~* Use of stimulant medications, sleep medications, nicotine patch, and other drugs thought to interfere with tDCS efficacy for seven days prior to and during study participation.~* Use of narcotic pain medication, benzodiazepines, or illicit drugs for seven days prior to and during study participation.~* Consumption of \>14 alcoholic drinks per week or positive screening on the CAGE.~* Skin conditions involving open sores on the scalp that would prevent proper application of the electrodes.~* Hairstyles that obstruct placement of the electrodes including cornrows, dreadlocks, braids or other hair accessories that cannot be removed.~* Other medical or other condition(s) that in the opinion of the investigators might compromise the objectives of the study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Active tDCS first (Type: ACTIVE_COMPARATOR): 2 mA of active tDCS applied over a 30-minute study session once per day for 5 consecutive days then sham tDCS after washout.
- Sham tDCS first (Type: SHAM_COMPARATOR): Stimulation mimicking the tDCS applied only briefly over a 30-minute study session once per day for 5 consecutive days then active tDCS after washout.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues